Feedback / Questions
romilkimab (SAR156597) - Sanofi
SAR156597: Submission in systemic scleroderma in 2022 or later
(Sanofi)
-
Feb 13, 2018 -
Q4 FY2017 Results
Regulatory
•
Immunology • Systemic Sclerosis
https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/investors/FY_2017_FINAL_Web.pdf
Feb 13, 2018
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious